[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334087-105":59,"doc-detail-334087-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pd-l1-expression-tumor-infiltrating-lymphocytes-and-mismatch-repair-proteins-status-in-digestive-neuroendocrine-neoplasms-exploring-their-potential-role-as-theragnostic-and-prognostic-biomarkers","PD-L1 expression, tumor-infiltrating lymphocytes, and mismatch repair proteins status in digestive neuroendocrine neoplasms - exploring their potential role as theragnostic and prognostic biomarkers","","Theragnostic biomarkers remain needed to identify patients with digestive neuroendocrine neoplasms (NENs) who could benefit from an optimal management strategy. The PD-1/PD-L1 axis is central to T-cell activation and anti-cancer immune responses, yet the biomarker value of PD-L1 expression in digestive NENs remains uncertain. Using 68 well-characterized digestive NENs, PD-L1 was assessed and TPS/CPS scores were calculated along with tumor-infiltrating lymphocytes and mismatch repair (MMR) protein expression. Results were correlated with clinicopathological features. PD-L1 expression was higher in NECs than in NETs, and MMR-deficient tumors plus intra-tumor immune infiltration were more frequent in NECs. No association emerged between PD-L1 expression and survival or other parameters. Findings suggest immune checkpoint inhibitors may be relevant mainly in selected NEC and MiNEN cases.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pd-l1-expression-tumor-infiltrating-lymphocytes-and-mismatch-repair-proteins-status-in-digestive-neuroendocrine-neoplasms-exploring-their-potential-role-as-theragnostic-and-prognostic-biomarkers/334087/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pd-l1-expression-tumor-infiltrating-lymphocytes-and-mismatch-repair-proteins-status-in-digestive-neuroendocrine-neoplasms-exploring-their-potential-role-as-theragnostic-and-prognostic-biomarkers/334087.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are theragnostic biomarkers important in digestive neuroendocrine neoplasms (NENs)?","Question",{"text":112,"@type":113},"Selecting appropriate patients for optimal management requires reliable theragnostic biomarkers. PD-L1-related biomarkers are considered because the PD-1/PD-L1 pathway influences T-cell activation and tumor immune responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the study find about PD-L1 expression across NETs, NECs, and MiNENs?",{"text":117,"@type":113},"PD-L1 expression was higher in NECs than in NETs, with TPS > 1% and/or CPS > 1 observed more frequently in NECs and in MiNENs than in NETs.",{"name":119,"@type":110,"acceptedAnswer":120},"Was PD-L1 expression linked to survival or other clinical features?",{"text":121,"@type":113},"No correlation was observed between PD-L1 expression and survival or other clinicopathological parameters, suggesting benefit from immune checkpoint inhibitors may be limited to selected cases rather than unselected patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334087,1790858233,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Virchows Archiv (2024) 485:841–851  \n[https://doi.org/10.1007/s00428-024-03825-5](https://doi.org/10.1007/s00428-024-03825-5)  \nPD‑L1 expression, tumor‑infiltrating lymphocytes, and mismatch repair proteins status in digestive neuroendocrine neoplasms:  \nexploring their potential role as theragnostic and prognostic biomarkers  \nEléonore Multone1 · Stefano La Rosa1,2,3 · Christine Sempoux1 · Silvia Uccella4,5  \nReceived: 11 February 2024 / Revised: 4 May 2024 / Accepted: 9 May 2024 / Published online: 21 May 2024 © The Author(s) 2024  \nAbstract  \nTheragnostic biomarkers are still needed to select patients with digestive neuroendocrine neoplasms (NENs) for an optimal management. The PD-1/PD-L1 pathway plays a pivotal role in T cells activation and host immune response to cancer and PD-L1 expression in tumor and/or immune cells is used to identify patients who would benefit of treatment with immune checkpoint inhibitors. However, its role as a biomarker is still unclear in digestive NENs. We investigated PD-L1 expression in 68 well-characterized digestive NENs (32 NETs, 32 NECs and 4 MiNENs) and TPS and CPS scores were calculated. In addition, tumor infiltrating T-lymphocytes and mismatch repair protein expression (MMR) were evaluated. All results were correlated with clinicopathological features. PD-L1 expression was higher in NECs than in NETs: TPS > 1% and/or CPS > 1 were observed in 16% of NETs, 68.8% of NECs and 50% of MiNENs (p: 0.05). The mean TPS score in positive cases was 6.3% in NETs, 16.2% in NECs and 5% in MiNENs. The CPS score was 4.8 in NETs, 8.1 in NECs and 6 in MiNENs. MMR-deficient neoplasms were more frequently observed in NECs than in NETs (p: \u003C 0.05) as well as intra-tumor immune infiltration (p: 0.00001) . No correlation between PD-L1 expression and survival or other clinicopathological parameters was observed. Our results suggest that treatment with immune checkpoint inhibitors may have a potential role only in selected cases, mainly in NECs and MiNENs.  \nKeywords PD-L1 · Mismatch repair protein · Tumor immune infiltration · Neuroendocrine neoplasm · Digestive system, neuroendocrine tumors, neuroendocrine carcinomas.  \nEléonore Multone and Stefano La Rosa share first co-authorship.  \n* Stefano La Rosa [stefano.larosa@uninsubria.it](stefano.larosa@uninsubria.it)  \n1 Institute of Pathology, Department of Laboratory Medicine and Pathology, University of Lausanne, Lausanne, Switzerland  \n2 Unit of Pathology, Department of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy  \n3 Unit of Pathology, Department of Oncology, ASST Sette Laghi, Varese, Italy  \n4 Department of Biomedical Sciences, Humanitas University, Milan, Italy  \n5 Pathology Service, Istituti Di Ricovero E Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy  \nIntroduction  \nGastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) encompass a heterogeneous group of malignant epithelial neoplastic proliferations including relatively indolent neuroendocrine tumors (NETs) and highly aggressive neuroendocrine carcinomas (NECs) [1] . NETs and NECs are two different diseases, with distinct morphological, molecular, and clinical features [2] . Based on their distinct biological features, they are treated differently in the context of clinically advanced disease. Generally speaking, platinum-based chemotherapy schedules are employed in patients with advanced NECs, whilst NETs can be managed with integrated approaches including surgery, somatostatin receptors targeted therapy, peptide receptor radionuclide therapy (PRRT), mTOR inhibitors (i.e., everolimus), antiangiogenic drugs (i.e., sunitinib), or chemotherapy depending on tumor  \ntype, grade, and stage [3–11] . However, despite the availability of multiple treatment options and guidelines from several scientific societies, there are still areas of controversy in advanced NENs treatment, for which there is limited guidance [12] . In this complex ","cbCainxDGAVl4oo7","https://ap.wps.com/l/cbCainxDGAVl4oo7","pdf",1595455,11,"English","# Abstract\n## Introduction\n## Materials and methods\n## Patients and samples","[{\"question\":\"Why are theragnostic biomarkers important in digestive neuroendocrine neoplasms (NENs)?\",\"answer\":\"Selecting appropriate patients for optimal management requires reliable theragnostic biomarkers. PD-L1-related biomarkers are considered because the PD-1/PD-L1 pathway influences T-cell activation and tumor immune responses.\"},{\"question\":\"What did the study find about PD-L1 expression across NETs, NECs, and MiNENs?\",\"answer\":\"PD-L1 expression was higher in NECs than in NETs, with TPS \\u003e 1% and/or CPS \\u003e 1 observed more frequently in NECs and in MiNENs than in NETs.\"},{\"question\":\"Was PD-L1 expression linked to survival or other clinical features?\",\"answer\":\"No correlation was observed between PD-L1 expression and survival or other clinicopathological parameters, suggesting benefit from immune checkpoint inhibitors may be limited to selected cases rather than unselected patients.\"}]","PD-L1 expression, tumor-infiltrating lymphocytes, and mismatch repair proteins status in digestive neuroendocrine neoplasms - exploring their potential role as theragnostic and prognostic biomarkers | PDF",1790005226,28]